MediPoint: Breast Cancer Imaging - Global Analysis and Market Forecasts -





 Published: May 2013 | Pages: 283 | Format: PDF 

 Description 

Breast cancer is the most common form of cancer in women in both the developed and developing world, but is a rare disease in men. The global incidence of breast cancer is increasing due to an increased lifespan and increasing adoption of western lifestyle risk factors. Early diagnosis of breast cancer is the foundation for increasing survival rates and diagnostic imaging is the most widely used technique to achieve early detection, making diagnostic imaging a cornerstone of breast cancer control.  

Diagnostic imaging is used for the early detection of breast cancer in asymptomatic patients in population-based screening programs in most developed countries, or for opportunistic screening in developing nations. Regardless of these differences, imaging has proved to be an indispensable tool in fighting breast cancer and has been proven to reduce mortality. This report provides an analysis of the mammography market (in relation to dedicated breast cancer screening and diagnosis), in the US, the 5EU (France, Germany, Italy, Spain, and UK), Brazil, and the APAC regions, including Japan, China, and India, and identifies the unmet needs in the market. This report also discusses physician attitudes towards current breast cancer screening and diagnostic techniques, and the future of breast cancer imaging modalities in the face of rapid technological advancements. 

 Table of Contents 

 1 Table of Contents 1 

 1.1 List of Tables 5 

 1.2 List of Figures 7 

 2 Executive Summary 9 

 2.1 Significant Unmet Needs and Challenges for the Global Breast Cancer Imaging Market 10 

 2.2 Future Landscape 10 

 2.3 What do Physicians Think? 11 

 3 Introduction 13 

 3.1 Catalyst 13 

 4 Disease Overview 14 

 4.1 Anatomy & Physiology of the Breast 14 

 4.2 Pathophysiology of Breast Cancer 14 

 4.3 Detection of Breast Cancer 14 

 4.4 Types of Breast Cancer 16 

 4.5 Clinical Presentation 17 

 4.6 Clinical Outcomes 17 

 4.6.1 Assessment Procedure 17 

 4.6.2 Screening Guidelines 21 

 4.7 Epidemiology of Breast Cancer 23 

 4.8 Economic Impact of Breast Cancer Imaging 26 

 5 Imaging Techniques 27 

 5.1 Mammography 27 

 5.1.1 Overview 27 

 5.1.2 Types of Mammography 29 

 5.2 Non-Mammographic Techniques 34 

 5.2.1 Breast Ultrasound Imaging 34 

 5.2.2 Breast Magnetic Resonance Imaging 34 

 5.3 Comparison of Mammography, Ultrasound, and MRI 35 

 5.4 Alternative Breast Imaging Techniques 36 

 5.4.1 Nuclear Imaging Techniques 37 

 5.4.2 Computed Tomography 38 

 5.4.3 Optical Breast Imaging 38 

 5.4.4 Electric Impedance-Based Techniques 39 

 5.4.5 Thermography 40 

 5.4.6 Elastography 40 

 5.4.7 Ductogram 40 

 6 Competitive Assessment 40 

 6.1 Overview 40 

 6.2 Film Screen Mammography 41 

 6.2.1 Performa (GE Healthcare) 41 

 6.2.2 Alpha RT/Alpha ST (GE Healthcare) 43 

 6.2.3 MAMMOMAT 1000 (Siemens Healthcare) 46 

 6.2.4 MAMMOMAT 3000 Nova (Siemens Healthcare) 48 

 6.2.5 M-IV/M-IV Platinum (Hologic) 50 

 6.2.6 MammoDiagnost (Philips Healthcare) 52 

 6.2.7 Planmed Nuance Classic (Planmed) 54 

 6.2.8 Planmed Sophie Classic (Planmed) 56 

 6.2.9 Analog Giotto Image (Internazionale Medico Scientifica) 57 

 6.2.10 HAWK-2M (Hologic) 59 

 6.2.11 MGU-1000A (Toshiba Medical Systems) 61 

 6.3 CR Mammography 62 

 6.3.1 Fuji Computed Radiography Mammography Suite (FCRMS) (Fujifilm Medical Systems) 62 

 6.3.2 KODAK DirectView (Carestream Health) 65 

 6.3.3 Xpress CR System (Konica Minolta) 66 

 6.3.4 REGIUS PureView (Konica Minolta) 67 

 6.3.5 Agfa CR Mammography Systems (DX-M, CR 30-Xm, and CR 85-X) (Agfa Healthcare) 69 

 6.4 Full-Field Digital Mammography 71 

 6.4.1 Selenia Dimensions (Hologic) 71 

 6.4.2 Selenia (Hologic) 74 

 6.4.3 Selenia S (Hologic) 76 

 6.4.4 Selenia Performance (Hologic) 77 

 6.4.5 Senographe DS (GE Healthcare) 79 

 6.4.6 Senographe Essential (GE Healthcare) 80 

 6.4.7 Senographe Care (GE Healthcare) 83 

 6.4.8 SenoBright CESM (GE Healthcare) 84 

 6.4.9 MAMMOMAT Inspiration (Siemens Healthcare) 86 

 6.4.10 Aspire HD (US)/Amulet (Outside the US) (Fujifilm) 88 

 6.4.11 MammoDiagnost DR (Philips Healthcare) 91 

 6.4.12 MicroDose (Philips Healthcare) 93 

 6.4.13 Giotto Image 3D/3DL (Internazionale Medico Scientifica) 95 

 6.4.14 Planmed Nuance/Nuance Excel (Planmed) 96 

 6.4.15 Fairy DR (Allengers Medical Systems) 99 

 6.4.16 Serenity 100 

 6.5 3D Mammography 101 

 6.5.1 Selenia Dimensions 3D System (Hologic) 101 

 6.5.2 True 3D Breast Tomosynthesis (Siemens Healthcare) 103 

 6.5.3 Giotto Tomo (Internazionale Medico Scientifica) 105 

 6.5.4 FUJIFILM 3Dimensional Mammography (Fujifilm) 107 

 6.6 Breast Ultrasound Imaging 108 

 6.6.1 somo.v Automated Breast Ultrasound (ABUS) (GE Healthcare) 109 

 6.6.2 SonoCine AWBUS (SonoCine) 111 

 6.6.3 ACUSON S2000 ABVS (Siemens Healthcare) 112 

 6.6.4 Terason t3200 Ultrasound System Breast Series (Terason Ultrasound) 114 

 6.7 Breast MRI 115 

 6.7.1 Aurora 1.5T Dedicated Breast MRI System (Aurora Imaging Technology) 115 

 6.8 Other Breast Imaging Techniques 117 

 6.8.1 PEM Flex Solo II (Naviscan) 117 

 6.8.2 Computerized Tomography Laser Mammography (CTLM) Model 1020 (Imaging Diagnostic Systems) 119 

 6.8.3 Dilon 6800/Dilon 6800 Acella (Dilon Diagnostics) 121 

 6.8.4 LumaGEM (Gamma Medica) 123 

 6.8.5 Discovery NM 750b (GE Healthcare) 125 

 7 Unmet Needs 127 

 7.1 Lower Radiation Dose 127 

 7.2 Increase Patient Comfort 128 

 7.3 Reduce False-Positives and False-Negatives 129 

 7.4 Loss of Sensitivity of Mammography in Dense Breasts 131 

 7.5 Unreliable Mammograms in Surgically-Operated Breasts and Breasts with Implants 133 

 7.6 Commitment to Training 133 

 8 Pipeline Products 136 

 8.1 Breast Cancer Imaging Pipeline Products Overview 136 

 8.2 GE Breast Tomosynthesis (GE Healthcare) 136 

 8.2.1 Overview and System Description 136 

 8.2.2 SWOT Analysis 138 

 8.3 MAMMOMAT Inspiration PRIME Edition 139 

 8.3.1 Overview 139 

 8.3.2 SWOT Analysis 139 

 8.4 MicroDose SI 140 

 8.4.1 Overview 140 

 8.4.2 SWOT Analysis 140 

 8.5 Selenia Dimensions 2D Contrast-Enhanced Digital Mammography (CEDM) 141 

 8.5.1 Overview 141 

 8.5.2SWOT Analysis 141 

 8.6 SenoCase 141 

 8.6.1 Overview 141 

 8.6.2 SWOT Analysis 142 

 8.7 Electrical Mammogram 143 

 8.7.1 Overview 143 

 8.7.2 SWOT Analysis 143 

 9 Industry Overview 144 

 9.1 Purchasing Cycle 144 

 9.1.1 Product Life Cycle 144 

 9.1.2 Cost Effectiveness in Screening Settings 146 

 9.1.3 Cost-Effectiveness in Diagnostic Settings 146 

 9.2 Market Access 147 

 9.2.1 Purchasing Decisions 147 

 9.2.2 Regulatory Process 147 

 9.3 Quality Assurance 150 

 9.3.1 US 150 

 9.3.2 EU 150 

 9.3.3 Brazil 150 

 9.3.4 Japan 151 

 9.3.5 China and India 151 

 9.4 Adoption of New Technologies 151 

 9.4.1 Influence of Clinical Trials Results 151 

 9.4.2 Reimbursement 152 

 9.4.3 Economic Resources 152 

 9.4.4 Low Breast Cancer Incidence and Absence of a National Screening Program 152 

 9.4.5 Competitive Advantage 153 

 9.5 Current Reimbursement Trends 154 

 9.5.1 US 154 

 9.5.2 Europe 155 

 9.5.3 France 156 

 9.5.4 Germany 156 

 9.5.5 Italy 156 

 9.5.6 Spain 156 

 9.5.7 UK 156 

 9.5.8 Japan 156 

 9.5.9 Brazil 157 

 9.5.10 China 157 

 9.5.11 India 157 

 9.6 Trends in Detector Technology for Digital Mammography 158 

 9.7 Evolving Scatter-Removal Mechanisms 161 

 9.8 Overdiagnosis 163 

 9.9 Malpractice Litigations 164 

 9.10 Mergers and Acquisitions/Key Partnerships 164 

 9.10.1 GE Healthcare Acquires U-Systems 165 

 9.10.2 Koninklijke Philips Electronics Acquires MicroDose Mammography from Sectra 165 

 9.10.3 Hologic Acquires Beijing Healthcome Technology 165 

 9.10.4 Hologic Acquires Sentinelle Medica 165 

 9.10.5 Koninklijke Philips Electronics Acquires Shanghai Apex Electronics Technology 165 

 9.10.6 Fujifilm Medical Systems acquired FUJIFILM-RU 165 

 9.10.7 Other Key Events 166 

 10 Current and Future Players 167 

 10.1 Overview 167 

 10.2 Trends in Corporate Strategy 168 

 10.3 Company Profiles 169 

 10.3.1 GE Healthcare 169 

 10.3.2 Hologic 171 

 10.3.3 Siemens 173 

 10.3.4 Koninklijke Philips Electronics 174 

 10.3.5 Fujifilm Medical Systems 175 

 10.3.6 Internazionale Medico Scientifica (IMS) 175 

 10.3.7 Planmed 177 

 10.3.8 Konica Minolta Medical Imaging 178 

 10.3.9 Agfa Healthcare 179 

 10.3.10 Carestream Health 180 

 10.3.11 SonoCine 181 

 10.3.12 Aurora Imaging Technology 182 

 10.3.13 Imaging Diagnostic Systems 183 

 10.3.14 Naviscan 184 

 10.3.15 Dilon Diagnostics 184 

 10.3.16 Gamma Medica 185 

 10.3.17 Allengers Medical Systems 186 

 11 Market Drivers & Opportunities 187 

 11.1 Market Drivers 187 

 11.1.1 Increase in the Incidence of Breast Cancer 187 

 11.1.2 Increased Awareness of the Benefits of Screening 187 

 11.1.3 Increased Breast Cancer Incidence Due to an Aging Population 188 

 11.1.4 FDA Reclassification of Mammography Equipment 188 

 11.1.5 New Technologies to Drive Market Growth 188 

 11.1.6 Changes in Age Inclusion Criteria in Breast Cancer Screening Programs 189 

 11.1.7 Adoption of Digital Mammography Units Worldwide 189 

 11.2 Opportunities 192 

 11.2.1 Emerging Economies Promise Future Growth 192 

 11.2.2 Invest in Emerging Technologies 192 

 11.2.3 Product Improvement 193 

 11.3 Market Barriers 194 

 11.3.1 Shortage of Dedicated Mammography Professionals 194 

 11.3.2 Reduced Hospital Budgets 194 

 11.3.3 Refurbished Equipment Sales 195 

 11.3.4 Reimbursement 195 

 11.3.5 Substitutes 195 

 12 Country Outlooks & Forecasts 196 

 12.1 Major Markets Overview 196 

 12.2 United States 199 

 12.2.1 United States Market Analysis 199 

 12.3 France 203 

 12.3.1 France Market Analysis 203 

 12.4 Germany 203 

 12.4.1 Germany Market Analysis 203 

 12.5 Italy 204 

 12.5.1 Italy Market Analysis 204 

 12.6 Spain 206 

 12.6.1 Spain Market Analysis 206 

 12.7 United Kingdom 207 

 12.7.1 United Kingdom Market Analysis 207 

 12.8 Japan 208 

 12.8.1 Japan Market Analysis 208 

 12.9 Brazil 209 

 12.9.1 Brazil Market Analysis 209 

 12.10 China 210 

 12.10.1 China Market Analysis 210 

 12.11 India 211 

 12.11.1 India Market Analysis 211 

 13 Appendix 213 

 13.1 Bibliography 213 

 13.2 Abbreviations 240 

 13.3 Report Methodology 245 

 13.3.1 Overview 245 

 13.3.2 Coverage 245 

 13.3.3 Secondary Research 245 

 13.3.4 Forecast Methodology 246 

 13.4 Physicians and Specialists Included in this Study 247 

 13.5 Primary Research 248 

 13.6 Physician Survey 248 

 13.7 About the Authors 249 

 13.7.1 Analysts 249 

 13.7.2 Global Head of Healthcare 250 

 13.8 Definitions 251 

 13.9 About MediPoint 252 

 13.10 About GlobalData 252 

 13.11 Contact Us 252 

 13.12 Disclaimer 252